Table 3 Baseline characteristics of enrolled patients in each included study.
Study ID | Groups | Race | |||||||
|---|---|---|---|---|---|---|---|---|---|
White | Black | Asian | American Indian or Alaska native | Hispanic or Latino | Not Hispanic or Latino | Native Hawaiian or other Pacific Islander | Others | ||
Diver S et al. 2021 | Tezepelumab | 54 (92%) | 2 (3%) | 2 (3%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (2%) |
Placebo | 55 (96%) | 1 (2%) | 1 (2%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | |
Menzies-Gow et al. 2021 | Tezepelumab | 332 (62.9%) | 30 (5.7%) | 146 (27.6%) | 0 (0%) | 0 (0%) | 0 (0%) | 1 (0.2%) | 19 (3.6%) |
Placebo | 327 (61.6%) | 31 (5.8%) | 149 (28%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 23 (4.3%) | |
Corren et al. 2017 | Tezepelumab low-dose | 131 (94.9%) | 4 (2.9%) | 3 (2.2%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) | 0 (0%) |
Tezepelumab medium-dose | 128 (93.4%) | 3 (2.2%) | 5 (3.6%) | 0 (0%) | 1 (0.7%) | 0 (0%) | 0 (0%) | 0 (0%) | |
Tezepelumab high-dose | 122 (89.1%) | 6 (4.4%) | 5 (3.6%) | 0 (0%) | 2 (1.5%) | 0 (0%) | 0 (0%) | 2 (1.5%) | |
Tezepelumab total | 381 (92.5%) | 13 (3.1%) | 13 (3.1%) | 0 (0%) | 3 (0.7%) | 0 (0%) | 0 (0%) | 2 (0.5%) | |
Placebo | 123 (89.1%) | 6 (4.3%) | 6 (4.3%) | 0 (0%) | 1 (0.7%) | 0 (0%) | 0 (0%) | 2 (1.4%) | |
Wechsler et al. 2022 | Tezepelumab | 62 (83.8%) | 1 (1.3%) | 11 (14.9%) | 0 (0%) | 10 | 64 | 0 (0%) | 0 (0%) |
Placebo | 64 (84.2%) | 0 (0%) | 11 (14.4%) | 0 (0%) | 14 | 62 | 0 (0%) | 1 | |
